GlassScriptPhysician profile
Rodel V Bobadilla
NPI 1942312111
$9,966.33
in general payments reported to CMS, 2019-2025
30 companies · $1,873 in 2025
The $1,873 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $722 · 2022: $2,494 · 2023: $2,538 · 2024: $2,339 · 2025: $1,873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,750.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,728.98 | 2021-2025 | |
| Amgen INC. | $972.07 | 2021-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $803.92 | 2021-2025 | Farxiga, Brilinta, Wainua |
| Merck Sharp & Dohme LLC | $667.54 | 2022-2025 | Verquvo |
| Pfizer INC. | $652.19 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $631.65 | 2021-2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $570.44 | 2022-2025 | Onpattro |
| Janssen Pharmaceuticals, INC | $508.56 | 2021-2024 | Xarelto |
| Boston Scientific Corporation | $455.64 | 2021-2025 | Watchman Access System, Cds - Mct/Cem Monitoring, Bodyguardian |
| Boehringer Ingelheim Pharmaceuticals, INC. | $400.87 | 2021-2025 | Jardiance |
| Philips North America LLC | $388.25 | 2022-2025 | (Ck4) Mcot, Event, Ecc Solutions |
| Bayer Healthcare Pharmaceuticals INC. | $367.97 | 2022-2025 | |
| Abbott Laboratories | $304.92 | 2022-2025 | Jot Dx, Aveir, Gallant |
| Esperion Therapeutics, INC. | $217.91 | 2021-2025 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $215.31 | 2021-2024 | Lifevest |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $194.36 | 2023-2025 | |
| Lexicon Pharmaceuticals, INC. | $150.01 | 2023-2024 | Inpefa |
| Altathera Pharmaceuticals LLC | $124.75 | 2025 | Sotalol Hydrochloride |
| Kiniksa Pharmaceuticals, LTD. | $120.20 | 2021-2023 | Arcalyst |
| Abiomed | $84.03 | 2024 | Impella |
| Atricure, INC. | $83.23 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Synergy Ablation System |
| Novo Nordisk INC | $57.47 | 2024-2025 | Wegovy |
| Actelion Pharmaceuticals US, INC. | $55.18 | 2022-2024 | Opsumit, Uptravi |
| Kiniksa Pharmaceuticals International, Plc | $46.13 | 2024 | Arcalyst |
| Arbor Pharmaceuticals, INC. | $35.51 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $31.29 | 2021-2022 | |
| Bridgebio Pharma, INC. | $28.67 | 2025 | Attruby |
| Kestra Medical Technology Services, INC. | $25.80 | 2024 | Assure Wcd |
| Daiichi Sankyo INC. | $25.49 | 2023 | Injectafer |
| Chiesi USA, INC. | $17.99 | 2023 | Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodel Bobadilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.